Ponatinib-Associated Cutaneous Eruptions-A Case Series and Review of Clinicopathologic Findings

Related Experiment Video

Updated: Aug 18, 2025

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.9K

Isaac Weber1, Catherine Gloss2, Brianna Castillo2

  • 1School of Medicine, University of Missouri, Columbia, MO.

The American Journal of Dermatopathology
|December 9, 2022
PubMed

Insights

Ponatinib treatment can cause skin reactions like pityriasis rubra pilaris-like eruptions. This study details two cases and reviews literature on ponatinib-induced rashes.

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Ponatinib is a tyrosine kinase inhibitor for leukemia.
  • Cutaneous toxicities, including various rash types, are common side effects.
  • Pityriasis rubra pilaris-like eruptions are infrequently reported with ponatinib.

Purpose of the Study:

  • To present clinicopathologic features of two cases of ponatinib-induced pityriasis rubra pilaris-like eruptions.
  • To classify all previously reported ponatinib-associated eruptions.
  • To discuss treatment and diagnostic challenges.

Main Methods:

  • Case report of two patients with ponatinib-induced rash.
  • Literature review and classification of reported ponatinib-associated cutaneous eruptions.
  • Analysis of clinical and histopathologic findings.

Main Results:

  • Detailed clinicopathologic findings for two cases of pityriasis rubra pilaris-like eruptions.
  • Systematic classification of diverse ponatinib-induced rash subtypes.
  • Identification of potential diagnostic pitfalls and treatment considerations.

Conclusions:

  • Ponatinib can induce pityriasis rubra pilaris-like skin eruptions.
  • Comprehensive understanding of these eruptions aids in diagnosis and management.
  • Further research is needed to elucidate mechanisms and optimize treatment.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.2K
The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

49.9K

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
231
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
242
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.0K